Piper Sandler analyst David Amsellem reiterated an Overweight rating and $44.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE